共 50 条
- [21] The FDA guidance for industry on PROs: the point of view of a pharmaceutical company [J]. Health and Quality of Life Outcomes, 4
- [25] Editorials - Academic psychiatry and the pharmaceutical industry: useful partnership or dangerous interaction? [J]. EPIDEMIOLOGIA E PSICHIATRIA SOCIALE-AN INTERNATIONAL JOURNAL FOR EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES, 2007, 16 (03): : 189 - 191
- [26] Qualified Statisticians in the European Pharmaceutical Industry: Report of a European Federation of Statisticians in the Pharmaceutical Industry (EFSPI) Working Group [J]. Drug information journal : DIJ / Drug Information Association, 1999, 33 (2): : 407 - 415
- [27] Qualified statisticians in the European pharmaceutical industry:: Report of a European Federation of Statisticians in the Pharmaceutical Industry (EFSPI) Working Group [J]. DRUG INFORMATION JOURNAL, 1999, 33 (02): : 407 - 415
- [28] The relationship between the pharmaceutical industry and medicine [J]. DIABETES OBESITY & METABOLISM, 2004, 6 (02): : 159 - 159
- [29] PARTNERSHIP BETWEEN COMMUNITY AND INDUSTRY ON ENVIRONMENTAL AWARENESS [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1992, 204 : 5 - CEI
- [30] FDA guidance for industry - Manufacturing, processing, or holding active pharmaceutical ingredients [J]. PHARMAZEUTISCHE INDUSTRIE, 1998, 60 (05): : 435 - 436